Drug Information

Drug General Information
Drug ID
D0Q0AP
Former ID
DNCL001825
Drug Name
BMS-582949
Drug Type
Small molecular drug
Indication Atherosclerosis; Psoriasis [ICD9: 414.0, 440, 696; ICD10:I70, L40] Phase 2 [522211], [542780]
Company
Bristol-Myers Squibb
Structure
Download
2D MOL
Formula
C22H26N6O2
InChI
InChI=1S/C22H26N6O2/c1-4-9-23-22(30)17-11-28-19(14(17)3)20(24-12-25-28)27-18-10-15(6-5-13(18)2)21(29)26-16-7-8-16/h5-6,10-12,16H,4,7-9H2,1-3H3,(H,23,30)(H,26,29)(H,24,25,27)
InChIKey
GDTQLZHHDRRBEB-UHFFFAOYSA-N
PubChem Compound ID
10409068
PubChem Substance ID
15426596, 22755586, 42239145, 77693239, 99376300, 104246258, 123106124, 139449490, 163642491, 170483336, 180418369, 198972880, 223366169, 226603762, 246470217
Target and Pathway
Target(s) Kinase Target Info Modulator [532303]
Stress kinase p38 Target Info Inhibitor [532303]
References
Ref 522211ClinicalTrials.gov (NCT00605735) PoC in Rheumatoid Arthritis With Methotrexate. U.S. National Institutes of Health.
Ref 542780(http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7838).
Ref 532303Synthesis and evaluation of carbamoylmethylene linked prodrugs of BMS-582949, a clinical p38alpha inhibitor. Bioorg Med Chem Lett. 2013 May 15;23(10):3028-33.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.